Daunomycin derivative with reduced cytotoxicity toward normal ce

Details Daunomycin derivative with reduced cytotoxicity toward normal ce Daunomycin derivative with reduced cytotoxicity toward normal ce

1995-04-17

1997-07-01

Peselev, Elli

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

A61K 3170

Patent

active

056438877

ABSTRACT:
Chemotherapeutic agents that exhibit cytotoxicity similar to that of daunomycin against cancer cells, but exhibit lessened cytotoxicity against normal, non-transformed cells are disclosed, as are compositions, processes for making and using the same. A contemplated chemotherapeutic agent is a daunomycin derivative whose structure corresponds to structural Formula I, wherein Ar is phenyl, 1-naphthyl or 2-naphthyl ##STR1##

REFERENCES:
patent: 4973674 (1990-11-01), Brasca et al.
patent: 4973675 (1990-11-01), Israel et al.
patent: 5413992 (1995-05-01), Nicolaou et al.
Johnson et al., The clinical impact of screening and other experimental tumor studies, Cancer Treatment Reviews, 2:1-31 (1975).

Affiliated with

Also associated with

Rating

Daunomycin derivative with reduced cytotoxicity toward normal ce does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Daunomycin derivative with reduced cytotoxicity toward normal ce, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Daunomycin derivative with reduced cytotoxicity toward normal ce will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-597198